Berdientje schreef op 29 juli 2016 09:01:
www.pharming.com/archives/2830Update
Important positioning continues for Pharming, in our belief, with increasing
Ruconest sales (beating our 2Q16 estimate), major Phase II prophylaxis data
in hand, and pipeline visibility expected later this year. We maintain our Buy
rating and $1.84 target.
Event
Pharming announced 2Q16 results, posting EPS of (€0.01), in line with our
estimate. Ruconest product revenue came in at €2.51 million, beating our
estimate of €1.98 million. U.S Ruconest revenue under partner Valeant (VRXNC)
was up ~33% QoQ. Quarter end cash was €21.7 million with burn primarily
associated with inventory costs for most recent batches of Ruconest
ROTH – PHGUF: 2Q16 Results; Building Revenue and Thesis.